“Low-Dose Aspirin Use After Diagnosis of Colorectal Cancer Does Not Increase Survival: A Case-Control Analysis of a Population-Based Cohort” Gastroenterol 2014; 146: 700-08. The authors performed a nested case-control analysis of a cohort of 4794 patients diagnosed with colorectal cancer. “There was no association between low-dose aspirin usage and colon cancer-specific mortality.” These study findings contradict previous studies. More trials are underway.
“Reduced Risk of Colorectal Cancer Up to 10 Years After Screening, Surveillance, or Diagnostic Colonoscopy” Gastroenterol 2014; 146: 709-17. Conclusion: “In a population-based case-control study, the risk of CRC was strongly reduced up to 10 years after colonoscopy for any indication. Risk was particularly low after screening colonoscopy, even for cancer in the right colon.” The odds ratio for CRC after screening colonoscopy was 0.09.
NEJM 2014; 370: 1287-97. Multitarget Stool DNA Testing for Colorectal-Cancer Screening. Among 9989 average-risk participants, this stool DNA assay identified more cancers than a fecal immunochemical test (FIT) but had more false positives.
Related blog posts:
gutsandgrowth 